Yousif Capital Management LLC Has $15.79 Million Position in Pfizer Inc. $PFE

Yousif Capital Management LLC cut its position in Pfizer Inc. (NYSE:PFE) by 3.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 619,842 shares of the biopharmaceutical company’s stock after selling 19,936 shares during the period. Yousif Capital Management LLC’s holdings in Pfizer were worth $15,794,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Capital Advisory Group Advisory Services LLC raised its stake in Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock worth $328,000 after buying an additional 388 shares during the period. Citizens National Bank Trust Department increased its holdings in shares of Pfizer by 0.9% in the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after acquiring an additional 395 shares in the last quarter. Peak Asset Management LLC raised its position in shares of Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after purchasing an additional 402 shares during the period. Able Wealth Management LLC lifted its holdings in shares of Pfizer by 2.0% during the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 413 shares in the last quarter. Finally, Boltwood Capital Management grew its position in shares of Pfizer by 0.7% in the 3rd quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock valued at $1,485,000 after purchasing an additional 420 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on PFE shares. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Scotiabank initiated coverage on shares of Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Finally, UBS Group reissued a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $28.06.

Pfizer Stock Performance

Shares of PFE opened at $25.23 on Tuesday. The stock has a market capitalization of $143.43 billion, a price-to-earnings ratio of 14.67 and a beta of 0.46. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The firm has a fifty day simple moving average of $25.11 and a 200 day simple moving average of $24.86. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s dividend payout ratio is 100.00%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.